Cargando…

Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events

In elite sport, the Athlete Biological Passport (ABP) was invented to tackle cheaters by monitoring closely changes in biological parameters, flagging atypical variations. The hematological module of the ABP was indeed adopted in 2011 by World Athletics (WA). This study estimates the prevalence of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Faiss, Raphael, Saugy, Jonas, Zollinger, Alix, Robinson, Neil, Schuetz, Frederic, Saugy, Martial, Garnier, Pierre-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052379/
https://www.ncbi.nlm.nih.gov/pubmed/32161553
http://dx.doi.org/10.3389/fphys.2020.00160
_version_ 1783502859775508480
author Faiss, Raphael
Saugy, Jonas
Zollinger, Alix
Robinson, Neil
Schuetz, Frederic
Saugy, Martial
Garnier, Pierre-Yves
author_facet Faiss, Raphael
Saugy, Jonas
Zollinger, Alix
Robinson, Neil
Schuetz, Frederic
Saugy, Martial
Garnier, Pierre-Yves
author_sort Faiss, Raphael
collection PubMed
description In elite sport, the Athlete Biological Passport (ABP) was invented to tackle cheaters by monitoring closely changes in biological parameters, flagging atypical variations. The hematological module of the ABP was indeed adopted in 2011 by World Athletics (WA). This study estimates the prevalence of blood doping based on hematological parameters in a large cohort of track and field athletes measured at two international major events (2011 and 2013 WA World Championships) with a hypothesized decrease in prevalence due to the ABP introduction. A total of 3683 blood samples were collected and analyzed from all participating athletes originating from 209 countries. The estimate of doping prevalence was obtained by using a Bayesian network with seven variables, as well as “blood doping” as a variable mimicking doping with low-doses of recombinant human erythropoietin (rhEPO), to generate reference cumulative distribution functions (CDFs) for the Abnormal Blood Profile Score (ABPS) from the ABP. Our results from robust hematological parameters indicate an estimation of an overall blood doping prevalence of 18% in 2011 and 15% in 2013 (non-significant difference) in average in endurance athletes [95% Confidence Interval (CI) 14–22 and 12–19% for 2011 and 2013, respectively]. A higher prevalence was observed in female athletes (22%, CI 16–28%) than in male athletes (15%, CI 9–20%) in 2011. In conclusion, this study presents the first comparison of blood doping prevalence in elite athletes based on biological measurements from major international events that may help scientists and experts to use the ABP in a more efficient and deterrent way.
format Online
Article
Text
id pubmed-7052379
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70523792020-03-11 Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events Faiss, Raphael Saugy, Jonas Zollinger, Alix Robinson, Neil Schuetz, Frederic Saugy, Martial Garnier, Pierre-Yves Front Physiol Physiology In elite sport, the Athlete Biological Passport (ABP) was invented to tackle cheaters by monitoring closely changes in biological parameters, flagging atypical variations. The hematological module of the ABP was indeed adopted in 2011 by World Athletics (WA). This study estimates the prevalence of blood doping based on hematological parameters in a large cohort of track and field athletes measured at two international major events (2011 and 2013 WA World Championships) with a hypothesized decrease in prevalence due to the ABP introduction. A total of 3683 blood samples were collected and analyzed from all participating athletes originating from 209 countries. The estimate of doping prevalence was obtained by using a Bayesian network with seven variables, as well as “blood doping” as a variable mimicking doping with low-doses of recombinant human erythropoietin (rhEPO), to generate reference cumulative distribution functions (CDFs) for the Abnormal Blood Profile Score (ABPS) from the ABP. Our results from robust hematological parameters indicate an estimation of an overall blood doping prevalence of 18% in 2011 and 15% in 2013 (non-significant difference) in average in endurance athletes [95% Confidence Interval (CI) 14–22 and 12–19% for 2011 and 2013, respectively]. A higher prevalence was observed in female athletes (22%, CI 16–28%) than in male athletes (15%, CI 9–20%) in 2011. In conclusion, this study presents the first comparison of blood doping prevalence in elite athletes based on biological measurements from major international events that may help scientists and experts to use the ABP in a more efficient and deterrent way. Frontiers Media S.A. 2020-02-25 /pmc/articles/PMC7052379/ /pubmed/32161553 http://dx.doi.org/10.3389/fphys.2020.00160 Text en Copyright © 2020 Faiss, Saugy, Zollinger, Robinson, Schuetz, Saugy and Garnier. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Faiss, Raphael
Saugy, Jonas
Zollinger, Alix
Robinson, Neil
Schuetz, Frederic
Saugy, Martial
Garnier, Pierre-Yves
Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events
title Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events
title_full Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events
title_fullStr Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events
title_full_unstemmed Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events
title_short Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events
title_sort prevalence estimate of blood doping in elite track and field athletes during two major international events
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052379/
https://www.ncbi.nlm.nih.gov/pubmed/32161553
http://dx.doi.org/10.3389/fphys.2020.00160
work_keys_str_mv AT faissraphael prevalenceestimateofblooddopinginelitetrackandfieldathletesduringtwomajorinternationalevents
AT saugyjonas prevalenceestimateofblooddopinginelitetrackandfieldathletesduringtwomajorinternationalevents
AT zollingeralix prevalenceestimateofblooddopinginelitetrackandfieldathletesduringtwomajorinternationalevents
AT robinsonneil prevalenceestimateofblooddopinginelitetrackandfieldathletesduringtwomajorinternationalevents
AT schuetzfrederic prevalenceestimateofblooddopinginelitetrackandfieldathletesduringtwomajorinternationalevents
AT saugymartial prevalenceestimateofblooddopinginelitetrackandfieldathletesduringtwomajorinternationalevents
AT garnierpierreyves prevalenceestimateofblooddopinginelitetrackandfieldathletesduringtwomajorinternationalevents